Immunic (IMUX) – Research Analysts’ Recent Ratings Updates

Immunic (NASDAQ: IMUX) has recently received a number of price target changes and ratings updates:

• 2/26/2025 – Immunic had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $17.00 price target on the stock.
• 2/22/2025 – Immunic was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 2/21/2025 – Immunic had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
• 2/20/2025 – Immunic had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $17.00 price target on the stock.
• 2/10/2025 – Immunic was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 1/31/2025 – Immunic was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 1/7/2025 – Immunic had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $17.00 price target on the stock.

Immunic Price Performance

Shares of IMUX stock opened at $1.17 on Thursday. The firm has a fifty day moving average of $1.04 and a 200-day moving average of $1.25. Immunic, Inc. has a 12-month low of $0.92 and a 12-month high of $2.11. The company has a market capitalization of $105.39 million, a price-to-earnings ratio of -0.95 and a beta of 1.89.

Institutional Investors Weigh In On Immunic

Large investors have recently made changes to their positions in the stock. Virtu Financial LLC bought a new stake in shares of Immunic during the third quarter worth $50,000. Invesco Ltd. bought a new stake in shares of Immunic during the fourth quarter worth $37,000. Jane Street Group LLC increased its position in shares of Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after acquiring an additional 38,553 shares in the last quarter. HB Wealth Management LLC bought a new stake in shares of Immunic during the fourth quarter worth $81,000. Finally, Barclays PLC bought a new position in Immunic in the fourth quarter valued at $84,000. Institutional investors own 51.82% of the company’s stock.

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.